Table 2.
Laboratory variables, CT scan and treatments of patients infected with COVID-19
| All patients (n = 33) | Worsening group (n = 13) | Improving group (n = 20) | p | |
|---|---|---|---|---|
| Laboratory variables | ||||
| WBC (109/L) | 4.8 (4.2–6.3) | 5.1 (4.6–7.3) | 4.4 (3.8–6.1) | 0.044 |
| Neutrophil (109/L) | 3.6 (2.7–4.3) | 3.7 (3.3–4.3) | 3.4 (2.2–5.0) | 0.146 |
| Lymphocyte (109/L) | 1.0 (0.6–1.2) | 1.0 (0.6–1.4) | 1.0 (0.8–1.2) | 0.668 |
| Albumin (g/L) | 30.1 (27.9–31.3) | 27.7 (26.2–29.3) | 31.0 (29.9–31.6) | 0.001 |
| Creatinine (µmol/L) | 65.2 (45.0–90.4) | 93.3 (47.2–138.4) | 646 (43.3–80.6) | 0.062 |
| Urea nitrogen (mmol/L) | 4.8 (3.4–6.8) | 5.9 (4.0–10.5) | 4.1 (3.2–6.1) | 0.04 |
| Uric acid (mmol/L) | 258.4 (187.8–376.8) | 333.5 (199.8–483.7) | 246.0 (168.3–296.7) | 0.071 |
| Procalcitonin (ng/ml) | 0.1 (0.5–0.2) | 0.1 (0.1–0.2) | 0.1 (0.0–0.2) | 0.255 |
| C-reactive protein (mg/L) | 32.7 (19.4–54.1) | 34.2 (24.0–59.0) | 32.6 (14.3–57.1) | 0.473 |
| Creatine jubase (U/L) | 124 (79.0–219.5) | 114 (82.0–443.0) | 126 (72.3–205.8) | 0.326 |
| Lactic dehydrogenase (U/L) | 287 (200.0–400.0) | 229 (151.0–417.0) | 309 (223.8–409.0) | 0.417 |
| d-dimer (ng/ml) | 1,520 (1,080–2,360) | 1,440 (970–3,515) | 1,590 (1,075–2,190) | 0.417 |
| CT Scan | 0.054 | |||
| Non apparent abnormality | 3 (9.1) | 0 (0) | 3 (15) | |
| One lung is involved | 3 (9.1) | 3 (23.1) | 0 (0) | |
| Both lungs are involved | 27 (81.8) | 10 (76.9) | 17 (85) | |
| Treatments | ||||
| Rehydration suppor | 9 (27.3) | 2 (15.4) | 7 (35) | 0.263 |
| Nutrition support | 19 (57.6) | 9 (69.2) | 10 (50) | 0.31 |
| Antibiotic | 32 (97) | 13 (100) | 19 (95) | 1 |
| Oxygenation index | 157 (125.5–208.0) | 127 (103.6–145.0) | 184 (154.0–229.5) | <0.001 |
Data are n (%) or median (interquartile range). WBC, white blood cell.